Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“Decision regret after adjuvant pembro in RCC isn’t driven by recurrence. It’s driven by long-term, low-grade toxicity that CTCAE never captures.
104 patients, median follow-up 30 months, Ottawa Decision Regret Scale plus patient-classified irAEs.
- 13% expressed moderate-high regret
- Regret tracked with patient-defined toxicity (26.9 life-changing vs 2.1 non-significant, p=0.0021), not CTCAE grade (G1-2 vs G3-4: 14.9 vs 15.1, p=0.23)
- Highest with permanent endocrine and musculoskeletal irAEs
Only 1 of 14 relapsed patients regretted the decision. A third of CTCAE G1-2 events were rated significant by patients. In a setting where surgery already cures most patients, the permanent low-grade toxicity is what they live with. Eye-opening data, and it should spur us to keep building novel methods of assessment beyond CTCAE.”
Other articles featuring Katy Beckermann on OncoDaily.
